Volition achieves ce mark for nu.q® nets test

To aid the detection and evaluation of diseases associated with netosis austin, texas , may 31, 2022 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has announced that its nu.q® nets test has been ce marked for the detection and evaluation of netosis, enabling clinical use in more than 27 countries across europe. netosis is a unique form of cell death that is characterized by the release of neutrophil extracellular traps ("nets"), composed of decondensed chromatin, that trap and kill bacteria and viral particles.
VNRX Ratings Summary
VNRX Quant Ranking